Download PDF
Thromb Haemost 1994; 72(04): 503-507
DOI: 10.1055/s-0038-1648903
Original Article
Schattauer GmbH Stuttgart

Serological and Virological Markers of Human Parvovirus B19 Infection in Sera of Hemophiliacs

A Große-Bley
1   The institute of Medical Microbiology and Immunology, Munich, Germany
,
A M Eis-Hübinger
1   The institute of Medical Microbiology and Immunology, Munich, Germany
,
R Kaiser
1   The institute of Medical Microbiology and Immunology, Munich, Germany
,
J Oldenburg
2   The institute of Experimental Hematology and Transfusion Medicine, University of Bonn, Bonn, Germany
,
H H Brackmann
2   The institute of Experimental Hematology and Transfusion Medicine, University of Bonn, Bonn, Germany
,
T F Schwarz
3   The Max v. Pettenkofer Institute for Hygiene and Medical Microbiology, University of Munich, Munich, Germany
,
K E Schneweis
1   The institute of Medical Microbiology and Immunology, Munich, Germany
› Author Affiliations
Further Information

Publication History

Received: 17 December 1993

Accepted after resubmission02 June 1994

Publication Date:
06 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

It is known that parvovirus B19 (B19) is transmitted to hemophiliacs by clotting factors prepared from human plasma. However, it is not clear whether B19 is also transmitted by the more recently used inactivated clotting factor preparations. Therefore, we investigated 69 hemophiliacs, mostly children, receiving only virus-inactivated clotting factors. 49 of them (71%) were B19 IgG-positive and 18 of the IgG-positive hemophiliacs (37%) were also B19 IgM-positive. In contrast, out of 73 age-matched controls only 10 (14%) were IgG-positive, two of them being also IgM-positive. In hemophiliacs treated before 1984 with noninactivated clotting factors, seroprevalence was very similar: 94/136 (69%) presented B19 IgG antibodies as compared to their age-matched controls with 16/50 (32%). Out of the 94 IgG-positive patients 24 (26%) were IgM-positive, whereas IgM antibodies were never found in 16 sera of 16 IgG-positive controls. In 4 out of 24 IgM positive hemophiliacs, B19 DNA was detected in the sera by using the polymerase chain reaction. However, B19 DNA was also found in 3/69 anti-B19 IgM-negative, HIV-infected hemophiliacs (all three patients in CDC stage IV). Since it seems unlikely that the results only represent passive acquisition of B19 DNA from blood products and induction of antibodies by immunization with inactivated antigen, the observations rather suggest that infection with B19 is transmitted by clotting factors, including those treated for virus inactivation.

 

  • References

  • 1 Craske J, Kirk P, Cohen B, Vandervelde EM. Commercial factor VIII associated hepatitis, 1974-75, in the United Kingdom: a retrospective survey. JHyg Camb 1978; 80: 327-336
    PubMedGoogle Scholar
  • 2 Ludlam CA, Steel CM, Cheingsong-Popov R, McClelland DBL, Tucker J, Tedder RS, Weiss RA, Philp I, Prescott RJ. Human T-lymphotropic virus type III (HTLV III) infection in seronegative haemophiliacs after transfusion of factor VIII. Lancet 1985; 11: 233-236
    PubMedGoogle Scholar
  • 3 Mortimer PP, Luban NLC, Kelleher JF, Cohen BJ. Transmission of serum parvovirus-like virus by clotting-factor concentrates. Lancet 1983; ii 482-464
    PubMedGoogle Scholar
  • 4 Frickhofen N, Young NS. A rapid method of sample preparation for detection of DNA viruses in human serum by polymerase chain reaction. J Virol Methods 1991; 35: 65-72
    PubMedGoogle Scholar
  • 4 Bailly E, Kleim JP, Schneweis KE, Van Loo B, Hammerstein U, Brack-mann HH. tiAbsence of human immunodeficiency virus (HIV) proviral sequences in seronegative hemophilic men and sexual partners of HIV-seropositive hemophiliacs. Transfusion 1991; 32: 104-108
    PubMedGoogle Scholar
  • 6 Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning. A laboratory manual. 2nd ed, Cold Spring Habor Laboratory Press, USA, PA 1989
    PubMedGoogle Scholar
  • 7 Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989; 339: 237-238
    CrossrefPubMedGoogle Scholar
  • 8 Schwarz TF, Jager G, Holzgreve W, Roggendorf M. Diagnosis of human parvovirus B19 infections by polymerase chain reaction. Scand J Infect Dis 1992; 24: 691-696
    CrossrefPubMedGoogle Scholar
  • 9 Bartolomei Corsi O, Azzi A, Morfini M, Fanci R, Rossi Ferrini P. Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates. J Med Virol 1988; 25: 165-170
    CrossrefPubMedGoogle Scholar
  • 10 Rollag H, Patou G, Pattison JR, Degre M, Evensen SA, Froland SS, Glom-stein A. Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools. Scand J Infect Dis 1991; 23: 675-679
    CrossrefPubMedGoogle Scholar
  • 11 Lyon DJ, Chapman CS, Martin C, Brown KE, Clewley JP, Flower AJE, Mitchell VE. Symptomatic parvovirus B19 infection and heat-treated factor IX concentrate. Lancet 1989; 1: 1085
    PubMedGoogle Scholar
  • 12 Morfini M, Longo G, Rossi Ferrini P, Azzi A, Zakrewska C, Ciappi S, Kolumban P. Hypoplastic anemia in a hemophiliac first infused with a solvent/detergent treated factor VIII concentrate: The role of human B19 parvovirus. Am J Hematol 1992; 39: 149-150
    CrossrefPubMedGoogle Scholar
  • 13 Cohen BJ, Field AM, Gudnadottir S, Beard S, Barbara JAJ. Blood donor screening for parvovirus B19. J Virol Methods 1990; 30: 233-238
    PubMedGoogle Scholar
  • 14 McOmish F, Yap PL, Jordan A, Hart H, Cohen BJ, Simmonds P. Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. J Clin Microbiol 1993; 31: 323-328
    PubMedGoogle Scholar
  • 15 Zakrzewska K, Azzi A, Patou G, Morfini M, Rafanelli D, Pattison JR. Human parvovirus B19 in clotting factor concentrates: B19 DNA detection by the nested polymerase chain reaction. Br J Haematol 1992; 81: 407-412
    CrossrefPubMedGoogle Scholar
  • 16 Lefrere J-J, Mariotti M, Thauvin M. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates. Lancet 1994; 343: 211-212
    CrossrefPubMedGoogle Scholar
  • 17 Schwarz TF, Roggendorf M, Hottentrager B, Stolz W, Schwinn H. Removal of parvovirus B19 from contaminated factor VIII during fractionation. J Med Virol 1991; 35: 28-31
    CrossrefPubMedGoogle Scholar
  • 18 Azzi A, Ciappi S, Zakvrzewska K, Morfini M, Mariani G, Mannucci PM. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol 1992; 39: 228-230
    CrossrefPubMedGoogle Scholar
  • 19 Santagostino E, Mannucci PM, Gringeri A, Azzi A, Morfini M. Eliminating parvovirus B19 from blood products. Lancet 1994; 343: 798
    CrossrefPubMedGoogle Scholar
  • 20 Williams MD, Cohen BJ, Beddall AC, Pasi KJ, Mortimer PP, Hill FGH. Transmission of human parvovirus B19 by coagulation factor concentrates. Vox Sang 1990; 58: 177-181
    CrossrefPubMedGoogle Scholar
  • 21 Musiani M, Azzi A, Zerbini M, Gibellini D, Venturoli S, Zakrzewska K, Re MC, Gentilomi G, Gallinella G, La Placa M. Nested polymerase chain reaction assay for the detection of B19 parvovirus DNA in human immunodeficiency virus patients. J Med Virol 1993; 40: 157-160
    CrossrefPubMedGoogle Scholar
  • 22 Frickhofen N, Young NS. Persistent parvovirus B19 infections in humans. Microbiol Pathogenesis 1989; 7: 319-327
    CrossrefPubMedGoogle Scholar
  • 23 Erdman DD, Usher MJ, Tsou C, Caul EO, Gary GW, Kajigaya S, Young NS, Anderson LJ. Human parvovirus B19 specific IgG, IgA, and IgM antibodies and DNA in serum specimens from persons with erythema infectio-sum. J Med Virol 1991; 35: 110-115
    CrossrefPubMedGoogle Scholar
  • 24 Torok TJ, Wang Q-Y, Gary jr GW, Yang C-F, Finch TM, Anderson LJ. Prenatal diagnosis of intrauterine infection with parvovirus B19 by polymerase chain reaction technique. Clin Infect Dis 1992; 14: 149-155
    CrossrefPubMedGoogle Scholar